About Prostaglandin E2 receptor EP1 subtype
Prostaglandin E2 receptor EP1 subtype (PTGER1) is a protein
from Homo sapiens identified by UniProt accession
P34995, 402 residues long.
MolForge cross-references it against 0 known binders and
298 disease associations.
Target properties
| Protein name | Prostaglandin E2 receptor EP1 subtype |
| UniProt accession | P34995 |
| Gene | PTGER1 |
| Organism | Homo sapiens |
| Length | 402 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (298)
Diseases linked to this target (Open Targets).
- erectile dysfunction · score 0.56
- pregnancy · score 0.46
- myocardial infarction · score 0.46
- Premature rupture of membranes · score 0.46
- pain · score 0.43
- cardiovascular disease · score 0.38
- diabetic nephropathy · score 0.37
- Patent ductus arteriosus · score 0.37
- acute kidney failure · score 0.37
- arterial occlusive disease · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P34995-F1 | alphafold | PREDICTED | 74.82 | — |
Amino-acid sequence (402 residues)
MSPCGPLNLS LAGEATTCAA PWVPNTSAVP PSGASPALPI FSMTLGAVSN LLALALLAQA AGRLRRRRSA ATFLLFVASL LATDLAGHVI PGALVLRLYT AGRAPAGGAC HFLGGCMVFF GLCPLLLGCG MAVERCVGVT RPLLHAARVS VARARLALAA VAAVALAVAL LPLARVGRYE LQYPGTWCFI GLGPPGGWRQ ALLAGLFASL GLVALLAALV CNTLSGLALL RARWRRRSRR PPPASGPDSR RRWGAHGPRS ASASSASSIA SASTFFGGSR SSGSARRARA HDVEMVGQLV GIMVVSCICW SPMLVLVALA VGGWSSTSLQ RPLFLAVRLA SWNQILDPWV YILLRQAVLR QLLRLLPPRA GAKGGPAGLG LTPSAWEASS LRSSRHSGLS HF
Explore Prostaglandin E2 receptor EP1 subtype with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets